These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Booth AD; Jayne DR; Kharbanda RK; McEniery CM; Mackenzie IS; Brown J; Wilkinson IB Circulation; 2004 Apr; 109(14):1718-23. PubMed ID: 15037536 [TBL] [Abstract][Full Text] [Related]
5. Biologics in vasculitides: Where do we stand, where do we go from now? Pazzola G; Muratore F; Pipitone N; Salvarani C Presse Med; 2015 Jun; 44(6 Pt 2):e231-9. PubMed ID: 26024760 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Hoffman GS; Merkel PA; Brasington RD; Lenschow DJ; Liang P Arthritis Rheum; 2004 Jul; 50(7):2296-304. PubMed ID: 15248230 [TBL] [Abstract][Full Text] [Related]
7. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781 [TBL] [Abstract][Full Text] [Related]
8. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012 [TBL] [Abstract][Full Text] [Related]
10. [Biotherapies for the treatment of asthma: are they the treatment of the future?]. Tonnel AB; Denis G; Lelong J Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S44-10S48. PubMed ID: 17127963 [No Abstract] [Full Text] [Related]
12. [Churg-Strauss syndrome--recent developments in diagnosis and treatment]. Hellmich B; Metzler C; Gross WL Dtsch Med Wochenschr; 2006 Oct; 131(41):2270-4. PubMed ID: 17036268 [No Abstract] [Full Text] [Related]
13. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Aeberli D; Oertle S; Mauron H; Reichenbach S; Jordi B; Villiger PM Swiss Med Wkly; 2002 Jul; 132(29-30):414-22. PubMed ID: 12428187 [TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Goek ON; Stone JH Curr Opin Rheumatol; 2005 May; 17(3):257-64. PubMed ID: 15838233 [TBL] [Abstract][Full Text] [Related]
15. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases]. Lapadula G Reumatismo; 2005; 57(4 Suppl):22-9. PubMed ID: 16385352 [TBL] [Abstract][Full Text] [Related]
16. [Common variable immunodeficiency and sarcoidosis: what is the link?]. Agostini C; Semenzato G Ann Ital Med Int; 2002; 17(2):77-80. PubMed ID: 12150049 [No Abstract] [Full Text] [Related]
17. [Biologicals in the treatment of rheumatic diseases]. Scherer HU; Burmester GR Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270 [No Abstract] [Full Text] [Related]
18. [Treatment of primary systemic vasculitis with TNF alpha-antagonists]. Gause A; Arbach O; Lamprecht P Z Rheumatol; 2003 Jun; 62(3):228-34. PubMed ID: 12827398 [TBL] [Abstract][Full Text] [Related]
19. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Calamia KT Adv Exp Med Biol; 2003; 528():545-9. PubMed ID: 12918761 [No Abstract] [Full Text] [Related]